ABVC BioPharma, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
ABVC BioPharma, Inc. (ABVC) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $218.49 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-08-12
- ABVC BioPharma, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for the quarter ending 2026-06-30 was $53.14K, a 83.90% decline year-over-year.
- ABVC BioPharma, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for the quarter ending 2026-03-31 was $165.35K, a 1514.42% increase year-over-year.
- ABVC BioPharma, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for the quarter ending 2025-06-30 was $330.04K.
- ABVC BioPharma, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for the quarter ending 2025-03-31 was $10.24K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 3 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 6 month |
|---|---|---|
| 2026-06-30 | $53.14K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $218.49K 10-Q · filed 2026-08-12 |
| 2026-03-31 | $165.35K 10-Q · filed 2026-05-18 | |
| 2025-06-30 | $330.04K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $340.28K 10-Q · filed 2026-08-12 |
| 2025-03-31 | $10.24K 10-Q · filed 2026-05-18 |